SSY Group (HKG:2005) secured Chinese regulatory approval for the production and registration of its sodium glycerophosphate injection, according to a Hong Kong bourse filing Monday.
The product is meant for adults who need parenteral nutrition, as well as patients with phosphorus deficiency.